Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8566079 | 0.99 | BDKRB2 (0.61) | BDKRB2 | |
| SCHEMBL8564173 | 0.91 | BDKRB2 (0.65) | BDKRB2 | |
| SCHEMBL8568367 | 0.88 | — | — | |
| SCHEMBL8560866 | 0.87 | BDKRB2 (0.61) | BDKRB2 | |
| SCHEMBL8566773 | 0.86 | — | — | |
| SCHEMBL8568514 | 0.86 | — | — | |
| SCHEMBL8565609 | 0.85 | BDKRB2 (0.71) | BDKRB2 | |
| SCHEMBL7664108 | 0.85 | BDKRB2 (0.59) | BDKRB2 | |
| SCHEMBL4601010 | 0.85 | BDKRB2 (0.61) | BDKRB2 | |
| SCHEMBL8565311 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1914236-A1 | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | Ortho-McNeil Pharmaceutical, Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| US-7358261-B2 | Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-6958349-B2 | Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2005-10-25 | — | — | US | disclosed |
| US-20050159443-A1 | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | CARSON JOHN R (US) | 2005-07-21 | — | — | US | disclosed |
| EP-1495017-A2 | NOVEL HETEROARYL ALKYLAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR MODULATORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040192720-A1 | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2003087090-A2 | NOVEL HETEROARYL ALKYLAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL,INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-6344462-B1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-05 | — | — | US | disclosed |
| US-6100284-A | ANTIALLERGENS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-08 | — | — | US | disclosed |
| US-6008229-A | TREATING ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASE, SHOCK, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-12-28 | — | — | US | disclosed |
| EP-0596406-B1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-12-16 | — | — | EP | disclosed |
| EP-0861243-A1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-09-02 | — | — | EP | disclosed |
| US-5750699-A | HALOGENATING OF CORRESPONDING COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| WO-1997011069-A1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-03-27 | — | — | WO | disclosed |
| US-5574042-A | ANTAGONIST FOR BRADYKININS AS ANTIALLERGENS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, SHOCK OR PAIN | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 1996-11-12 | — | — | US | disclosed |
| EP-0596406-A1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192720-A1 | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | BDKRB2, BDKRB1, MRGPRX1 | BDKRB2 1/4885 |
| US-20050159443-A1 | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | BDKRB2, BDKRB1, MRGPRX1 | BDKRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.